Tavapadon

DB14899ApprovedSmall molecule

Tavapadon is an oral non-ergot dopamine agonist acting as a selective D1/D5 receptor partial agonist, indicated for the treatment of Parkinson's disease in adults. A medication taken by mouth to treat Parkinson's disease in adults.

Chemical structure of Tavapadon
Mechanism
Curator reviewed · 1 reference
Primary indication
Tavapadon is indicated for the treatment of Parkinson's disease (PD) in adults.Curator reviewed · 1 structured indication
Formula / weight
C19H16F3N3O3 · 391.35 g/mol (avg)
First approval
United States, 2026
Also known as
PF-06649751
Code names
CVL-751

Resolves to

Compound
UNIIPT4P8MJP8LCAS1643489-24-0ChEMBLCHEMBL3697617ChEBI755713PubChem86764100
Structure
InChIKeyAKQXQLUNFKDZBN-UHFFFAOYSA-NSMILESCN1C(=O)NC(=O)C(C)=C1C1=C(C)C=C(OC2=NC=CC=C2C(F)(F)F)C=C1
Targets
P21728DRD1P21918DRD5
Transporters
Q9UNQ0ABCG2P08183ABCB1Q96FL8SLC47A1

What you can answer from here — as of October 20, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3TransportersSubstrate / inhibitor direction, not just membership
Listed above
13Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
6Marketed productsAcross 1 country and 1 labeller
Sign in
16+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tavapadon, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In